Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Business Wire•23/07/2026•08:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.